Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems

References

• Sitcharungsi R, Sirivichayakul C. Allergic diseases and helminth infections. Pathog Glob Health. 2013;107(3):110–115. doi:10.1179/2047773213Y.000000008023683364
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N. Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J Asthma Allergy. 2017;10:237. doi:10.2147/JAA.S14410028919788
   PubMed Web of Science ®Google Scholar
• Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–13.30056149
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention: A Pocket Guide for Health Professionals; updated 2019 Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf. Accessed 25 November, 2019.
   Google Scholar
• Yalcin AD, Bisgin A, Cetinkaya R, Yildirim M, Gorczynski RM. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. Clin Lab. 2013;59(1–2):71–77. doi:10.7754/Clin.Lab.2012.12040623505909
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy. 2008;63(4):409–417. doi:10.1111/all.2008.63.issue-418315729
   PubMed Web of Science ®Google Scholar
• Cruz A, Lima F, Sarinho E, et al. Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197–207. doi:10.1111/cea.2007.37.issue-217250692
   PubMed Web of Science ®Google Scholar
• Lanier B Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Paper Presented At: Allergy & Asthma Proceedings. 2006.
   Google Scholar
• Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Safety. 2018;41(5):489–509. doi:10.1007/s40264-017-0636-929411337
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa180409229782217
   PubMed Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FER, Wallace DV. American academy of allergy, asthma & immunology/American college of allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–1377. doi:10.1016/j.jaci.2007.09.03217996286
   PubMed Web of Science ®Google Scholar
• McCracken J, Tripple J, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol. 2016;16(4):375. doi:10.1097/ACI.000000000000028427362324
   PubMed Web of Science ®Google Scholar
• Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71–81. doi:10.2147/JAA.S7804927110133
   PubMed Web of Science ®Google Scholar
• Benralizumab (FASENRA) Reference ID: 4125440. Published 2016 Available from: https://www.fda.gov/media/110322/download. Accessed 518, 2019.
   Google Scholar
• Administration FaD. Dupilumab: Reference ID: 4337903. 2018.
   Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med. 2017;4:135. doi:10.3389/fmed.2017.00135
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751 e1747. doi:10.1016/j.jaci.2018.09.03330359681
   PubMed Web of Science ®Google Scholar
• Bradford ES, Albers FC, Gilson MJ, et al. Long-term safety of mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study In: A34 ASTHMA CLINICAL STUDIES I; 2018:A1367–A1367. American Thoracic Society.
   Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi:10.1067/mai.2001.11788011496232
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi:10.1016/j.jaci.2015.09.00826518090
   PubMed Web of Science ®Google Scholar
• Corren J, Casale T, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788–797. doi:10.1111/cea.2009.39.issue-619302249
   PubMed Web of Science ®Google Scholar
• Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med. 1994;180(1):43–51. doi:10.1084/jem.180.1.438006599
   PubMed Web of Science ®Google Scholar
• Korenaga M, Watanabe N, Tada I. Effects of anti-IgE monoclonal antibody on a primary infection of Strongyloides ratti in mice. Parasitol Res. 1991;77(4):362–363. doi:10.1007/BF009309171866426
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Novel Drug Approvals for 2016. Food and Drug Administration Published 2018 Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2016. Accessed 11 22, 2019
   Google Scholar
• Administration USFaD. Novel Drug Approvals for 2017. Food and Drug Administration Published 2018 Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017. Accessed 6, 2019.
   Google Scholar
• Highlights of Prescribing Information: Dupixent. Food and Drug Administration; 2019.
   Google Scholar
• Administration USFaD. Clinical Review: Biologics Licensing Application No. 103976 Xolair (Omalizumab). Food and Drug Administration; 2009.
   Google Scholar
• Administration USFaD. Novel Drug Approvals for 2015. Food and Drug Administration; 2016.
   Google Scholar
• Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. Ther Clin Risk Manag. 2017;13:1139–1149. doi:10.2147/TCRM28979129
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa180409329782224
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. The Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar